There are currently three TNF agents on the market for RA; among these, infliximab is a chimeric monoclonal antibody against TNF-α administered as an infusion. Golimumab is similar to infliximab, except that it has been engineered to be fully human and is given as a subcutaneous injection.

Follow this link:
Golimumab Shows Promise for the Treatment of Rheumatoid Arthritis

Estrogens are known to modify immunologic responses and the modulation of rheumatoid arthritis (RA) disease activity during pregnancy is well documented. However, whether physiologic replacement of estrogen and other hormones after menopause adversely affects RA outcomes is controversial. Here, Wallitt et al (Arthritis Care & Research 2008; 59: 302) explore whether postmenopausal hormone replacement therapy (HRT) increases the incidence or severity of RA in women enrolled in the Women Health Initiative (WHI) trials.

Read more from the original source:
Does Postmenopausal Hormone Replacement Affect Rheumatoid Arthritis Outcomes?